TARRYTOWN, N.Y., Aug. 15, 2019 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation
at the Morgan Stanley 17th Annual Global Healthcare Conference at
8:10 a.m. Eastern Time on Monday,
September 9, 2019.
The session may be accessed from the "Investors &
Media" page of Regeneron's website at
http://investor.regeneron.com/events-and-presentations. A
replay of the webcast will be archived on the Company's website and
will be available for 30 days.
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company that invents
life-transforming medicines for people with serious diseases.
Founded and led for 30 years by physician-scientists, Regeneron's
unique ability to repeatedly and consistently translate science
into medicine has led to seven FDA-approved treatments and numerous
product candidates in development, all of which were homegrown in
Regeneron's laboratories. Regeneron's medicines and pipeline
are designed to help patients with eye diseases, allergic and
inflammatory diseases, cancer, cardiovascular and metabolic
diseases, pain, infectious diseases, and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through its proprietary
VelociSuite® technologies, such as
VelocImmune® which produces optimized fully-human
antibodies, and ambitious research initiatives such as the
Regeneron Genetics Center, which is conducting one of the largest
genetics sequencing efforts in the world.
For additional information about the company, please visit
www.regeneron.com or follow @Regeneron on Twitter.
Contact Information:
Investor Relations
Justin Holko
914.847.7786
mark.hudson@regeneron.com
Corporate Communications
Hala Mirza
914.847.3422
hala.mirza@regeneron.com
View original
content:http://www.prnewswire.com/news-releases/regeneron-announces-upcoming-investor-conference-presentation-300901849.html
SOURCE Regeneron Pharmaceuticals, Inc.